Reduction in thrombogenic activity and thrombocytopenia after transcatheter aortic valve implantation - The ATTRACTIVE-TTAS study
Masanobu Ishii, Koichi Kaikita, Tatsuro Mitsuse, Nobuhiro Nakanishi, Yu Oimatsu, Takayoshi Yamashita, Suguru Nagamatsu, Noriaki Tabata, Koichiro Fujisue, Daisuke Sueta, Seiji Takashio, Yuichiro Arima, Kenji Sakamoto, Eiichiro Yamamoto, Kenichi Tsujita, Masanobu Ishii, Koichi Kaikita, Tatsuro Mitsuse, Nobuhiro Nakanishi, Yu Oimatsu, Takayoshi Yamashita, Suguru Nagamatsu, Noriaki Tabata, Koichiro Fujisue, Daisuke Sueta, Seiji Takashio, Yuichiro Arima, Kenji Sakamoto, Eiichiro Yamamoto, Kenichi Tsujita
Abstract
Introduction: Bleeding complications after transcatheter aortic valve implantation (TAVI) is a major problem in clinical practice. However, there is few information on thrombogenicity after TAVI. The aim of this study was to establish a monitoring of total thrombogenicity in perioperative TAVI using the Total Thrombus-formation Analysis System (T-TAS), a microchip-based flow chamber system for analysis of thrombus formation under flow condition.
Methods: Twenty-three patients with severe aortic stenosis who underwent TAVI between August 2017 and March 2018 at Kumamoto university hospital were enrolled. After exclusion, data of 21 patients were analyzed. Blood samples were obtained before, 2, 7, and 30 days after TAVI. Thrombogenicity were assessed by the T-TAS to compute the area under the curve (AUC) (AR10-AUC30) in the AR chip. We also measured platelet count, high-molecular-weight von Willebrand factor (HMW-vWF) multimers, and plasma thrombopoietin. Computational fluid dynamics (CFD) analysis was performed to calculate the wall shear stress (WSS).
Results: The AR10-AUC30 levels and platelet counts were significantly lower at 2 days post-TAVI, and then increased gradually. HMW-vWF multimers, and plasma thrombopoietin, were significantly higher at 2 days post-TAVI, compared with before TAVI. CFD analysis showed that WSS of the aortic valve and posterior ascending aortic wall were significantly lower after TAVI than before-TAVI. Multivariate analysis identified max velocity measured by echocardiography, platelet count, and D-dimer as significant determinants of AR10-AUC30, representing total thrombogenicity.
Conclusions: Although HMW-vWF multimers improved earlier after TAVI, total thrombogenic activity evaluated by T-TAS remained relatively low followed by improvement in thrombogenic activity at 30 days after TAVI.Clinical Trial Registration: https://ichgcp.net/clinical-trials-registry/NCT03248232" title="See in ClinicalTrials.gov">NCT03248232.
Keywords: Severe aortic stenosis; Thrombocytopenia; Thrombogenicity; Transcatheter aortic valve implantation.
Figures
References
- Kodali S., Thourani V.H., White J., Malaisrie S.C., Lim S., Greason K.L. Early clinical and echocardiographic outcomes after SAPIEN 3 transcatheter aortic valve replacement in inoperable, high-risk and intermediate-risk patients with aortic stenosis. Eur. Heart J. 2016;37(28):2252–2262.
- Leon M.B., Smith C.R., Mack M., Miller D.C., Moses J.W., Svensson L.G. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N. Engl. J. Med. 2010;363(17):1597–1607.
- Popma J.J., Adams D.H., Reardon M.J., Yakubov S.J., Kleiman N.S., Heimansohn D. Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery. J. Am. Coll. Cardiol. 2014;63(19):1972–1981.
- Genereux P., Cohen D.J., Williams M.R., Mack M., Kodali S.K., Svensson L.G. Bleeding complications after surgical aortic valve replacement compared with transcatheter aortic valve replacement: insights from the PARTNER I Trial (Placement of Aortic Transcatheter Valve) J. Am. Coll. Cardiol. 2014;63(11):1100–1109.
- Tabata N., Tsujita K. Antithrombotic regimens in patients undergoing Transcatheter aortic valve implantation. Circ. J. 2017;81(3):308–309.
- Hassell M.E., Hildick-Smith D., Durand E., Kikkert W.J., Wiegerinck E.M., Stabile E. Antiplatelet therapy following transcatheter aortic valve implantation. Heart. 2015;101(14):1118–1125.
- Ichibori Y., Mizote I., Maeda K., Onishi T., Ohtani T., Yamaguchi O. Clinical outcomes and bioprosthetic valve function after Transcatheter aortic valve implantation under dual antiplatelet therapy vs. aspirin alone. Circ. J. 2017;81(3):397–404.
- Loscalzo J. From clinical observation to mechanism--Heyde's syndrome. N. Engl. J. Med. 2012;367(20):1954–1956.
- Vincentelli A., Susen S., Le Tourneau T., Six I., Fabre O., Juthier F. Acquired von Willebrand syndrome in aortic stenosis. N. Engl. J. Med. 2003;349(4):343–349.
- Sueta D., Kaikita K., Okamoto N., Arima Y., Ishii M., Ito M. A novel quantitative assessment of whole blood thrombogenicity in patients treated with a non-vitamin K oral anticoagulant. Int. J. Cardiol. 2015;197:98–100.
- Sueta D., Kaikita K., Ogawa H. Letter by Sueta et al regarding article, "urgent need to measure effects of direct Oral anticoagulants". Circulation. 2016;134(21):e496–e497.
- Arima Y., Kaikita K., Ishii M., Ito M., Sueta D., Oimatsu Y. Assessment of platelet-derived thrombogenicity with the total thrombus-formation analysis system in coronary artery disease patients receiving antiplatelet therapy. J. Thromb. Haemost. 2016;14(4):850–859.
- Ishii M., Kaikita K., Ito M., Sueta D., Arima Y., Takashio S. Direct Oral anticoagulants form Thrombus different from warfarin in a microchip flow chamber system. Sci. Rep. 2017;7(1):7399.
- Oimatsu Y., Kaikita K., Ishii M., Mitsuse T., Ito M., Arima Y. Total Thrombus-formation analysis system predicts Periprocedural bleeding events in patients with coronary artery disease undergoing percutaneous coronary intervention. J. Am. Heart Assoc. 2017;6(4)
- Ito M., Kaikita K., Sueta D., Ishii M., Oimatsu Y., Arima Y. Total Thrombus-formation analysis system (T-TAS) can predict Periprocedural bleeding events in patients undergoing catheter ablation for atrial fibrillation. J. Am. Heart Assoc. 2016;5(1)
- Hosokawa K., Ohnishi T., Kondo T., Fukasawa M., Koide T., Maruyama I. A novel automated microchip flow-chamber system to quantitatively evaluate thrombus formation and antithrombotic agents under blood flow conditions. J. Thromb. Haemost. 2011;9(10):2029–2037.
- Hosokawa K., Ohnishi T., Fukasawa M., Kondo T., Sameshima H., Koide T. A microchip flow-chamber system for quantitative assessment of the platelet thrombus formation process. Microvasc. Res. 2012;83(2):154–161.
- Ruggeri Z.M., Zimmerman T.S. The complex multimeric composition of factor VIII/von Willebrand factor. Blood. 1981;57(6):1140–1143.
- Van Belle E., Rauch A., Vincentelli A., Jeanpierre E., Legendre P., Juthier F. Von Willebrand factor as a biological sensor of blood flow to monitor percutaneous aortic valve interventions. Circ. Res. 2015;116(7):1193–1201.
- Itatani K., Miyaji K., Qian Y., Liu J.L., Miyakoshi T., Murakami A. Influence of surgical arch reconstruction methods on single ventricle workload in the Norwood procedure. J. Thorac. Cardiovasc. Surg. 2012;144(1):130–138.
- Numata S., Itatani K., Kanda K., Doi K., Yamazaki S., Morimoto K. Blood flow analysis of the aortic arch using computational fluid dynamics. Eur. J. Cardiothorac. Surg. 2016;49(6):1578–1585.
- Miyazaki S., Itatani K., Furusawa T., Nishino T., Sugiyama M., Takehara Y. Validation of numerical simulation methods in aortic arch using 4D flow MRI. Heart Vessel. 2017;32(8):1032–1044.
- Kappetein A.P., Head S.J., Genereux P., Piazza N., van Mieghem N.M., Blackstone E.H. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the valve academic research Consortium-2 consensus document. Eur. Heart J. 2012;33(19):2403–2418.
- Van Belle E., Rauch A., Vincent F., Robin E., Kibler M., Labreuche J. Von Willebrand factor Multimers during Transcatheter aortic-valve replacement. N. Engl. J. Med. 2016;375(4):335–344.
- Mitrosz M., Kazimierczyk R., Sobkowicz B., Waszkiewicz E., Kralisz P., Frank M. The causes of thrombocytopenia after transcatheter aortic valve implantation. Thromb. Res. 2017;156:39–44.
- Flaherty M.P., Mohsen A., JBt Moore, Bartoli C.R., Schneibel E., Rawasia W. Predictors and clinical impact of pre-existing and acquired thrombocytopenia following transcatheter aortic valve replacement. Catheter. Cardiovasc. Interv. 2015;85(1):118–129.
- Dvir D., Genereux P., Barbash I.M., Kodali S., Ben-Dor I., Williams M. Acquired thrombocytopenia after transcatheter aortic valve replacement: clinical correlates and association with outcomes. Eur. Heart J. 2014;35(38):2663–2671.
- Takada Y., Shinkai F., Kondo S., Yamamoto S., Tsuboi H., Korenaga R. Fluid shear stress increases the expression of thrombomodulin by cultured human endothelial cells. Biochem. Biophys. Res. Commun. 1994;205(2):1345–1352.
- Ishibazawa A., Nagaoka T., Takahashi T., Yamamoto K., Kamiya A., Ando J. Effects of shear stress on the gene expressions of endothelial nitric oxide synthase, endothelin-1, and thrombomodulin in human retinal microvascular endothelial cells. Invest. Ophthalmol. Vis. Sci. 2011;52(11):8496–8504.
- Malek A.M., Jackman R., Rosenberg R.D., Izumo S. Endothelial expression of thrombomodulin is reversibly regulated by fluid shear stress. Circ. Res. 1994;74(5):852–860.
- Yau J.W., Teoh H., Verma S. Endothelial cell control of thrombosis. BMC Cardiovasc. Disord. 2015;15:130.
Source: PubMed